Drugmakers, insurers, hospitals, pharmacies, medical devices, clinical updates, and healthcare business leaders.
Moderna’s stock jumped sharply in the afternoon session after the company said its personalized mRNA cancer vaccine, developed with Merck, met key targets in a late-stage study, according to a market report.
THE APEX TIMES
THE APEX TIMES
In an interview on Yahoo Finance, bioethicist and physician Ezekiel Emanuel characterized late-stage findings for a Moderna and Merck mRNA cancer vaccine as a “grand slam,” while offering limited specifics on efficacy or safety details.
THE APEX TIMES
A look at 2026 performance so far points to Merck (MRK) as the clear leader among several major U.S. pharmaceutical names, with Amgen (AMGN) ranking second and Pfizer (PFE) lagging.
THE APEX TIMES
The companies announced a strategic research collaboration aimed at developing trans-amplifying RNA, or taRNA, vaccine candidates for infectious diseases, bringing Lilly’s scale to Amplitude’s platform approach.
THE APEX TIMES
In premarket and early trading on Aug. 19, 2026, investors bid up several biotechnology and health-care stocks after news that a Moderna-Merck cancer vaccine cleared a late-stage trial milestone, according to a market post that also linked the move to Tempus’s planned acquisition of Personalis.
THE APEX TIMES
Moderna (MRNA) was up sharply on Wednesday, with market trackers suggesting the company’s stock could be on course for a 100% gain in a single day, a feat last seen in the S&P 500 more than a decade ago.
THE APEX TIMES
Stocks tied to biotechnology and semiconductors led a broad session, with Moderna jumping, Merck advancing, Micron trading lower, and Marvell surging after disclosing a warrant tied to Google.
THE APEX TIMES
A July 20, 2026 merger announcement priced Personalis at a major markup through a Tempus AI acquisition structured as a 100% stock transaction, spotlighting the growing cash value of precision-medicine data platforms.
THE APEX TIMES
The stock roughly doubled following renewed investor optimism after a cancer-vaccine trial outcome, after which William Blair upgraded Moderna’s shares.
